Novartis AG (NYSE:NVS) Holdings Boosted by Catalyst Capital Advisors LLC

Catalyst Capital Advisors LLC boosted its position in shares of Novartis AG (NYSE:NVSGet Rating) by 8.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 40,080 shares of the company’s stock after purchasing an additional 3,000 shares during the period. Catalyst Capital Advisors LLC’s holdings in Novartis were worth $3,506,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NVS. OLD Mission Capital LLC grew its holdings in shares of Novartis by 85.1% during the 3rd quarter. OLD Mission Capital LLC now owns 367,985 shares of the company’s stock valued at $32,000,000 after acquiring an additional 169,219 shares in the last quarter. Keudell Morrison Wealth Management grew its holdings in shares of Novartis by 7.3% during the 3rd quarter. Keudell Morrison Wealth Management now owns 3,947 shares of the company’s stock valued at $323,000 after acquiring an additional 268 shares in the last quarter. EagleClaw Capital Managment LLC grew its holdings in shares of Novartis by 2.7% during the 3rd quarter. EagleClaw Capital Managment LLC now owns 24,560 shares of the company’s stock valued at $2,005,000 after acquiring an additional 650 shares in the last quarter. Barclays PLC grew its holdings in shares of Novartis by 94.7% during the 3rd quarter. Barclays PLC now owns 106,883 shares of the company’s stock valued at $8,741,000 after acquiring an additional 51,994 shares in the last quarter. Finally, Creative Planning boosted its holdings in Novartis by 45.8% in the third quarter. Creative Planning now owns 105,127 shares of the company’s stock worth $8,597,000 after purchasing an additional 33,024 shares in the last quarter. Hedge funds and other institutional investors own 9.40% of the company’s stock.

A number of brokerages recently issued reports on NVS. Stifel Nicolaus began coverage on shares of Novartis in a report on Monday, February 28th. They issued a “hold” rating for the company. upgraded shares of Novartis from a “hold” rating to a “buy” rating in a report on Thursday, April 14th. Morgan Stanley upped their price objective on shares of Novartis from CHF 90 to CHF 94 in a report on Friday, May 6th. UBS Group upped their price objective on shares of Novartis from CHF 85 to CHF 88 and gave the stock a “neutral” rating in a report on Wednesday, April 27th. Finally, Wolfe Research cut shares of Novartis from an “outperform” rating to a “market perform” rating in a report on Monday, May 9th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $90.50.

Shares of NVS traded up $0.44 during trading hours on Friday, reaching $85.82. 2,519,380 shares of the company traded hands, compared to its average volume of 2,351,205. The stock’s fifty day moving average is $87.69 and its 200 day moving average is $85.99. The stock has a market cap of $191.96 billion, a P/E ratio of 7.99, a price-to-earnings-growth ratio of 2.45 and a beta of 0.52. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.01 and a current ratio of 1.25. Novartis AG has a 1-year low of $79.09 and a 1-year high of $95.17.

Novartis (NYSE:NVSGet Rating) last announced its quarterly earnings data on Tuesday, April 26th. The company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.44 by $0.02. The business had revenue of $12.53 billion during the quarter, compared to analyst estimates of $12.61 billion. Novartis had a net margin of 46.47% and a return on equity of 23.16%. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.52 earnings per share. On average, equities research analysts predict that Novartis AG will post 6.07 EPS for the current year.

Novartis Profile (Get Rating)

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.

Read More

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.